A Quarter-Billion Bet on Sight
Science Corporation closed a $230 million Series C round yesterday, one of the largest funding events in the medical BCI space this year. The capital will accelerate commercialization of PRIMA, the company’s photovoltaic retinal implant designed to restore functional vision in patients with geographic atrophy, the advanced form of dry age-related macular degeneration.
The technology works differently than most neural interfaces. PRIMA uses an array of microphotovoltaic pixels implanted beneath the retina. These pixels convert pulsed near-infrared light from specialized glasses into electrical signals that stimulate surviving retinal neurons. The approach bypasses degenerated photoreceptors while preserving the eye’s natural neural pathways.
Founded by Max Hodak, former president of Neuralink, Science Corporation has moved quickly since its 2021 inception. The company published clinical data showing PRIMA recipients could read large print and recognize faces, functional milestones that matter more than acuity charts. Geographic atrophy affects over 5 million people globally, a patient population with few treatment options and progressive, irreversible vision loss.
Commercial Momentum
The funding round’s size signals investor confidence in nearer-term commercialization timelines compared to other BCI applications. Restoring partial vision requires fewer implanted electrodes and less complex decoding than motor BCIs. The regulatory pathway, while rigorous, follows established precedents for retinal prosthetics.
Science Corporation faces competition from Second Sight Medical Products and Pixium Vision, both developing visual prosthetics. Yet PRIMA’s subretinal approach and photovoltaic design offer potential advantages in resolution and power efficiency. The device requires no transcutaneous wiring, reducing infection risk.
The capital will fund manufacturing scale-up, additional clinical trials, and regulatory submissions across multiple markets. Science Corporation has not disclosed which investors led the round or specific commercialization timelines.
Why This Matters
Sensory restoration represents BCI technology’s most tractable near-term application. Success here creates regulatory templates, manufacturing infrastructure, and clinical expertise that transfer to more complex neural interfaces. Vision restoration also generates compelling outcome data. A patient reading again or recognizing a grandchild’s face provides clearer endpoints than incremental mobility improvements.
The funding environment for BCI companies has tightened since 2021’s peak. That Science Corporation secured this round suggests investors see differentiated technology and realistic commercial timelines. How quickly PRIMA moves through remaining regulatory gates will test whether medical BCIs can transition from research curiosities to scalable healthcare products.